Aziyo Biologics
David Colpman has served as a member of the board of directors since October 2022. Mr. Colpman was the managing partner of Colpman Consulting Ltd., a business development consultancy, from July 2014 to March 2020. Prior to this, Mr. Colpman was a senior vice president at Shire Plc from 1999 to 2014. Prior to Shire Plc, Mr. Colpman had senior roles in business development at Novo Nordisk A/S, Glaxo Wellcome Plc, and Boots Pharmaceuticals Ltd. Mr. Colpman currently serves on the board of OakHill Bio, a private clinical-stage neonatology and rare disease therapeutics company. In addition, he is currently an advisor to HighCape Capital, an affiliate of HighCape Partners, which is an investment fund and a controlling stockholder of the Company. Mr. Colpman received a B.Sc. from Portsmouth University in the field of pharmacy.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Aziyo Biologics
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015, the Company has expanded through acquisitions and strategic partnerships, creating a high-growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular, and other medical specialties.